The COVID-19 pandemic has not only impacted access to healthcare, but also significantly disrupted the conduct of clinical trials investigating therapies intended to treat cardiovascular (CV) diseases.
New trial starts have been halted or delayed, and enrollment in ongoing trials has stalled. Continuity of participation in active studies has necessitated adaptations and creative solutions to ensure adherence and retention. What’s more, because patient populations are particularly vulnerable to infection and COVID-19, sponsors are expected to be extra vigilant to ensure patients stay safe. Here we report on measures that can be implemented to reduce the disruption of CV trials, while maintaining patient safety.
Developing an integrated solution to keep clinical trials on track during COVID-19
To overcome operational challenges, clinical trial stakeholders need to adapt how they manage CV trials in response to constantly changing pandemic-related restrictions. Specifically, they should start by developing an integrated solution that is tailored to meet the needs of each individual study. This would include the following:
- Track latest information on the pandemic: Track the impact of COVID-19 on a country and individual site level in real-time. To mitigate delays in site activation and screening, use the data generated from the tracking to redeploy study resources where appropriate.
- Initiate remote trial monitoring: Remote source data verification, remote source data review and remote/central monitoring should be employed to ensure that protocol compliance, and accurate and timely data collection are being performed where on-site monitoring is no longer feasible.
- Employ direct-to-subject shipping and home healthcare: When sites cannot directly dispense study medication to participants, arrangements should be made for secure direct-to-subject shipping. In situations where a laboratory test result is needed to authorise the dispensation of a study drug, home healthcare nurses can be used to ensure that dosing is not disrupted. Further, local travel restrictions, limited access to sites, and trial subject concerns for potential exposure to the coronavirus have increased the probability of missed study visits. Therefore, sponsors should consider using alternative means such as telemedicine. Also, when possible, home health services should be employed to increase compliance and reduce the need for subjects to travel to sites.
- Communicate change: Maintaining regular contact with participants to communicate protocol changes and to facilitate compliance and study retention is particularly crucial during this pandemic. When needed, urgent operational changes in study conduct should be promptly communicated to research staff, participants and local institutional review boards before protocol amendments can be implemented.
Sponsors who utilise a fully integrated approach driven by an overarching COVID-19 regulatory guidance will be well positioned to adapt to the challenges of the evolving pandemic, ensure patient safety, reduce disruptions to trial timelines and stay compliant.
Trial committees, core labs, and endpoint adjudication
In addition to overcoming the operational challenges during the pandemic, maintaining a sense of continuity with regard to trial committees, core labs and endpoint adjudication is essential to the successful continuation of the trial.
Trial committees composed of key opinion leaders and independent experts are commonly employed in CV trials to monitor patient safety and provide scientific insight, and to ensure data quality, integrity and operational oversight. These committees are ever more critical in light of the pandemic. However, committee members may have transitioned to working remotely, which could impact their participation. Therefore, it is best to work with a third party who can manage the logistics for these committee members and facilitate remote meetings.
Core labs often provide unbiased and consistent analyses in CV trials. Data is typically transferred to the core lab in an electronic and secure environment. To facilitate timely analyses, developing a compliant platform to provide high-quality images for review and an efficient communications system for relaying information is critical for those reviewers who must work remotely. Proactive communication with sites and reviewers ensures “reads” have been performed on a timely basis and information has been relayed back to sites promptly.
Endpoint adjudication committees are commonly used in CV trials. They are made up of expert cardiologists who render a decision regarding a clinical cardiac event in accordance with a prespecified event definition.
During this pandemic, a number of COVID-19-related cardiac events have been reported in persons hospitalised with the virus. In these situations, it will be necessary to collect additional source documentation — including COVID-19 testing results — to adjudicate a cardiac event, and attribute causality, especially in the case of death. Finally, one will need to factor in these cardiac events when interpreting the effect of an investigational treatment on adjudicated cardiac events (e.g., the primary endpoint of a trial).
Deploy connected devices and mobile health solutions
Connected devices and mobile health solutions can help to minimise COVID-19-related disruptions to CV clinical trials and can be incorporated into future trials. For example, when an echocardiogram is required, but the patient is unable or unwilling to go to a study centre for the procedure, several options can be considered beyond extending the visit window. One alternative is to perform the study at a more accessible site. Another may be to use high-end mobile echocardiogram equipment, with trained sonographers conducting the echocardiogram in the subject’s home. The use of this equipment can not only minimise physical patient contact with healthcare providers, but also enable the collection of important safety and efficacy data outside the centre in real time.
Future direction
The lessons learned during the COVID-19 pandemic will enable a more efficient and, hopefully, a greater number of hybrid trial designs to further ease site and patient burdens, and facilitate responses to unforeseen risks to study execution. Additionally, the use of digital health technologies, along with home healthcare visits and telehealth, may improve monitoring of clinical trial participation.
Learn more about ICON’s cardiovascular expertise in our white paper: Mitigating the impact of COVID-19 on cardiovascular trials at ICONplc.com/CVTrials
Cardiovascular, Metabolic and Circulation insights
ICON's Cardiovascular team contributes regularly to industry publications and media coverage of cardiovascular clinical trials. Stay up to date with ICON's latest thought leadership on cardiovascular clinical trials.
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption: Surveying the industry's evolving landscape
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel